Mupirocin Ointment to Eliminate Nasal Carriage of Staphylococcus Aureus in HIV Infection
Status:
Completed
Trial end date:
2006-04-01
Target enrollment:
Participant gender:
Summary
Staphylococcus aureus is a bacteria that causes serious, often life threatening infections
including pneumonia, wound, and bloodstream infections. Persons with AIDS are at high risk
for S. aureus infections. They are also at high risk for nasal carriage of S. aureus. In
fact, nasal carriage is a known risk factor for subsequent S. aureus infection. Topical
mupirocin, an antibiotic when applied to the anterior nares, is a safe, effective way to
eliminate S. aureus colonization. Some studies have shown that mupirocin can also decrease
the risk of S. aureus infection, but many of those studies utilized historical controls and
none were rigorously tested among AIDS patients over an extended period of time.
The main purpose of this randomized, double-blinded, placebo controlled study is to determine
if mupirocin can eliminate S. aureus nasal colonization in residents at PSI (inpatient, drug
rehabilitation facility for AIDS patients in the Bronx.) PSI residents currently have a high
incidence of S. aureus nasal colonization and infection. Nasal cultures followed by twice
daily application of mupirocin vs. placebo for five days will be performed on a monthly basis
for 8 months. the study will examine whether mupirocin decreases the incidence of S. aureus
infections and prevents S. aureus nasal colonization. The study is important because it may
show that mupirocin is an effective way to eliminate nasal colonization and prevent S. aureus
infections in AIDS patients, among those at highest risk for serious S. aureus infection.
Hypothesis: Monthly application of mupirocin will reduce nasal colonization with S.aureus
Phase:
Phase 4
Details
Lead Sponsor:
Columbia University
Collaborators:
GlaxoSmithKline National Institute of Allergy and Infectious Diseases (NIAID)